Sherwin Stephen A
- SEC CIK
- 0001079462
In the past year, 1 open-market sale filing worth $4.13M and no purchases.
Current role at each company
- NBIX Neurocrine Biosciences IncDirectoras of Sep 3, 2026
- BIIB Biogen Inc.Directoras of Jun 11, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $4.13M
- 1 filing
- Net
- −$4.13M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Sherwin Stephen A as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
NBIX Neurocrine Biosciences Inc
Director5 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2026 (view filing) | Jun 5 | 4 days | Sherwin Stephen ADirector | SSale | −25.0K | $165.32 | −$4.13M | −61.2%15.9K after | 5 lots10b5-1 |
| Feb 14, 2025 (view filing) | Feb 13 | 1 day | Sherwin Stephen ADirector | SSale | −13.8K | $116.69 | −$1.61M | −56.4%10.7K after | 10b5-1 |
| May 30, 2024 (view filing) | May 29 | 1 day | Sherwin Stephen ADirector | SSale | −40.0K | $133.46 | −$5.34M | −60.1%26.5K after | 2 lots10b5-1 |
| Jan 5, 2023 (view filing) | Jan 3 | 2 days | Sherwin Stephen ADirector | SSale | −30.0K | $118.86 | −$3.57M | −54.5%25.1K after | 2 lots |
| Jan 26, 2022 (view filing) | Jan 24 | 2 days | Sherwin Stephen ADirector | SSale | −15.0K | $74.43 | −$1.12M | −37.4%25.1K after |
BIIB Biogen Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2025 (view filing) | Mar 7 | 3 days | Sherwin Stephen ADirector | SSale | −8.76K | $150.02 | −$1.31M | −43.6%11.3K after | 10b5-1 |